Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment

International Journal of Infectious Diseases

Volumn 15, Issue 11, 2011, Pages

  Yu, Jian Wu ^a   Sun, Li Jie ^a   Zhao, Yong Hua ^a   Kang, Peng ^a   Yan, Bing Zhu ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Age; Chronic hepatitis C; Sex; Sustained virologic response; SVR

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SEROTYPE; SEX DIFFERENCE; SUSTAINED VIROLOGIC RESPONSE;

ADULT; AGE FACTORS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SEX FACTORS; TREATMENT OUTCOME;

EID: 80054916178     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.05.018     Document Type: Article

References (21)

1. Shimizu I. Impact of oestrogens on the progression of liver disease. Liver Int 2003, 23:63-69.
2. Massard J., Ratziu V., Thabut D., Moussalli J., Lebray P., Benhamou Y., et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006, 44:S19-S24.
3. Codes L., Matos L., Paraná R. Chronic hepatitis C and fibrosis: evidence for possible estrogen benefits. Braz J Infect Dis 2007, 11:371-374.
4. Shimizu I., Inoue H., Yano M., Shinomiya H., Wada S., Tsuji Y., et al. Estrogen receptor levels and lipid peroxidation in hepatocellular carcinoma with hepatitis C virus infection. Liver 2001, 21:342-349.
5. Di Martino V., Lebray P., Myers R.P., Pannier E., Paradis V., Charlotte F., et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 2004, 40:1426-1433.
6. Hung C.H., Lee C.M., Lu S.N., Wang J.H., Chen C.H., Hu T.H., et al. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int 2006, 26:1079-1086.
7. Huang C.F., Yang J.F., Dai C.Y., Huang J.F., Hou N.J., Hsieh M.Y., et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010, 201:751-759.
8. Dienstag J.L., McHutchison J.G. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006, 130:225-230.
9. Lee S.S., Heathcote E.J., Reddy K.R., Zeuzem S., Fried M.W., Wright T.L., et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002, 37:500-506.
10. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
11. Hayashi J., Kishihara Y., Ueno K., Yamaji K., Kawakami Y., Furusyo N., et al. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 1998, 158:177-181.
12. Sezaki H., Suzuki F., Kawamura Y., Yatsuji H., Hosaka T., Akuta N., et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009, 54:1317-1324.
13. Narciso-Schiavon J.L., Schiavon Lde L., Carvalho-Filho R.J., Sampaio J.P., Batah P.N., Barbosa D.V., et al. Gender influence on treatment of chronic hepatitis C genotype 1. Rev Soc Bras Med Trop 2010, 43:217-223.
14. Kainuma M., Furusyo N., Kajiwara E., Takahashi K., Nomura H., Tanabe Y., et al. Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010, 16:4400-4409.
15. Reddy K.R., Shiffman M.L., Morgan T.R., Zeuzem S., Hadziyannis S., Hamzeh F.M., et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007, 5:124-129.
16. Khosla S., Melton L.J., Atkinson E.J., O'Fallon W.M., Klee G.G., Riggs B.L. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998, 83:2266-2274.
17. Richardson S.J., Senikas V., Nelson J.F. Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 1987, 65:1231-1237.
18. Codes L., Asselah T., Cazals-Hatem D., Tubach F., Vidaud D., Paraná R., et al. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. Gut 2007, 56:390-395.
19. Takaki S., Tsubota A., Hosaka T., Akuta N., Someya T., Kobayashi M., et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa 2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004, 39:668-673.
20. Afdhal N.H., Dieterich D.T., Pockros P.J., Schiff E.R., Shiffman M.L., Sulkowski M.S., et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004, 126:1302-1311.
21. Yu J.W., Wang G.Q., Sun L.J., Li X.G., Li S.C. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007, 22:832-836.